Successfully Printing Profit Growth of 109 Percent in 2025, Phapros Shares 15 Percent Dividend

Photo: Special

PT Phapros Tbk (PEHA), a leading pharmaceutical company in Indonesia, has successfully held its Annual General Meeting of Shareholders (AGMS) in Jakarta, Thursday, June 11.

The Phapros Annual General Meeting of Shareholders discussed five main agendas, including: 1) Approval of the Company's Annual Report and approval of the consolidated financial statements of the company for the 2025 Fiscal Year, 2) Approval of the use of the company's net profit, 3) Determination of salaries/honoraria, facilities, and benefits for the 2026 Fiscal Year, 4) Appointment of public accountants and 5) Material transactions.

In the Annual General Meeting of Shareholders of Phapros, shareholders have approved all agendas proposed by the company, including on the agenda of the use of the company's net profit for the 2025 Book Year, namely the distribution of cash dividends to shareholders of 15 percent of the company's net profit and the remainder will be used as a reserve fund for CAPEX compliance. Company.

In the presentation of the Annual General Meeting of Shareholders, Intan Abdams Katoppo, President Director of PT Phapros Tbk, presented the Phapros Annual Financial Report for the 2025 Fiscal Year. On this occasion, he said that the Company managed to achieve excellent performance in 2025 with significant growth in sales and net profit.

Therefore, according to him, the Company agreed to distribute dividends to shareholders. Intan emphasized that this decision is a form of appreciation of the company for the loyalty of PEHA investors and shows a stable financial condition and positive cash flow.

"Phapros is committed to continue to provide added value for shareholders, including through dividend distribution. This reflects Phapros' solid and healthy financial performance and has strong business fundamentals. The company is on the right track to maintain profitability sustainability. For this reason, we are optimistic that the company will continue to provide added value for shareholders in the coming years," said Intan in the Public Exposure (Public Expose) of Phapros in Jakarta, Thursday, June 11.

Phapros managed to record a net profit of IDR 27.4 billion in 2025, growing 109 percent, compared to 2024 which suffered a loss of IDR 290.6 billion. This PEHA profit was driven by double-digit sales growth and the success of operational efficiency strategies.

As seen in the Company's audited financial statements that have been published, Phapros sales in 2025 amounted to IDR 940.88 billion, up 26.34 percent year-on-year (year-on-year/y-oy). The increase in sales occurred across all product segments. The over-the-counter (OTC) segment grew 43.20 percent y-o-y, the logo generic drug (OGB) segment grew 13.95 percent y-o-y, and the ethical segment soared to 55 percent y-o-y.

In addition, throughout 2025, the company was also able to reduce the cost of goods sold (cost of goods sold/COGS) by 5.41 percent to IDR 448.37 billion compared to the previous year's IDR 474.03 billion. This slick performance is further strengthened by the company's ability to reduce business expenses which were successfully reduced by 14.64 percent to IDR 406.43 billion in 2025 compared to IDR 476.12 billion in 2024.

Cost Restructuring

Intan explained that the cost restructuring strategy throughout 2025 has proven successful in achieving production efficiency. This can be seen from the 5.41 percent decrease in COGS. The COGS ratio to sales in 2025 also decreased significantly to 47.65 percent compared to 2024 of 63.65 percent. The low COGS ratio to sales indicates that the production process is very efficient and has a larger gross profit margin.

Another positive achievement is the success in reducing liabilities in 2025 of Rp959.70 billion down 7.45 percent (y-o-y) compared to 2024 of Rp1,036.92 billion.

The success in cutting liabilities has encouraged an increase in equity in 2025 to IDR 427.47 billion, up 8.74 percent compared to the previous year of IDR 393.12 billion. This equity growth also indicates that the company is increasingly valuable for owners/shareholders. Not only profit, Phapros is also able to maintain cash flow (cashflow) well. Net cash flow from the company's operating activities was positive IDR 123.757 billion, with a cash balance as of December 31, 2025 of IDR 120.98 billion, up 31.49 percent compared to the same period last year of IDR 92 billion.

"The positive parameters that have been carved throughout the 2025 fiscal year, are a new spirit for management to prove that Phapros can continue to grow and meet shareholders' expectations sustainably. Phapros can definitely, Phapros is healthy, Healthy is Phapros," concluded Intan.